Aim To determine radiologic, clinic and laboratory characteristics of COVID-19 positive patients with acute arterial occlusion and compare them with post COVID-19 and non-COVID-19 patients. Methods In this retrospective study, 53 patients with acute occlusion of peripheral arteries admitted to the University Clinical Hospital Mostar in the period between 29 February 2020 and 30 September 2021 were involved. The first group was made of COVID-19 positive patients, the second group were post COVID-19 patients and a control group were non-COVID-19 patients. Results Most patients were males, 37 (69.8%). The average age of COVID positive patients was 66.09±11.25 years, post COVID-19 patients 71.33±5.22 years and COVID-19 negative patients 69.82±1.99 years. Lower extremities were most affected, 38 (71.6%), without significant alteration in the coagulogram. Acute arterial occlusion occurred about 2 weeks after the beginning of COVID-19 or at the time of the first appearance of symptoms. Conclusion We have to take special care about patients with risk factors for developing acute arterial occlusion due to thromboembolism or thrombosis 10 days after the beginning of the disease. We also recommend the use of low molecular weight heparin (LMWH) and monitoring coagulation state due to anti Xa and thromboelastometry.
Mueller A, Mcnamara M, Sinclair D. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020:9959–81.
2
Kunutsor S, Laukkanen J. Incidence of venous and arterial thromboembolic complications in CO-VID-19: a systematic review and meta-analysis. Thromb Res 2020:27–30.
3
Brown W, Lunati M, Maceroli M, Ernst A, Staley C, Johnson R, et al. Ability of thromboelastography to detect hypercoagulability: a systematic review and meta-analysis. J Orthop Trauma 2020:278–86.
4
Junqueira D, Zorzela L, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2017.
5
Lovecchio F. Heparin-induced thrombocytopenia. ClinToxicol (Phila) 2014:579–83.
6
Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta 2020:180–94.
7
Zuin M, Rigatelli G, Zuliani G, Roncon L. The risk of thrombosis after acute-COVID-19 infection. QJM 2021:619–20.
8
Gonzalez-Fajardo J, Ansuategui M, Romero C, Comanges A, Gómez-Arbeláez D, Ibarra G, et al. Mortality of covid-19 patients with vascular thrombotic complications. Med Clin (Barc) n.d.:112–7.
9
Garg K, Barfield M, Pezold M, Sadek M, Cayne N, Lugo J, et al. Arterial thromboembolism associated with COVID-19 and elevated D-dimer levels. J VascSurg Cases Innov Tech 2020:348–51.
10
Minno D, Ambrosino A, Calcaterra P, I, Minno D, Mnd. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020:763–71.
11
Cheruiyot I, Kipkorir V, Ngure B, Misiani M, Munguti J, Ogeng ’, et al. Arterial Thrombosis in Coronavirus Disease 2019 Patients: A rapid systematic review. Ann Vasc Surg 2021:273–81.
12
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Humanitas CO-VID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital. Thromb Res 2020:9–14.
13
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet 2020:497–506.
14
Ya’qoub L, Elgendy I, Pepine C. Sex and gender differences in COVID-19: More to be learned. Am Heart J Plus 2021:100011.
15
Su W, Qiu Z, Zhou L, Hou J, Wang Y, Huang F, et al. Sex differences in clinical characteristics and risk factors for mortality among severe patients with CO-VID-19: a retrospective study. Aging (Albany NY) 2020:18833–43.
16
Naqvi I, Alam M, Rehan M, Mahmood K, Aurangzeb M, Talib A. COVID-19-associated coagulopathy and thromboembolism: determination of their patterns and risk factors as predictors of mortality among severe COVID-19 patients. Curr Vasc Pharmacol 2022:77–86.
17
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost 2020:1094–9.
18
Levy J, Koster A, Quinones Q, Milling T, Key N. Antifibrinolytic therapy and perioperative considerations. Anesthesiology 2018:657–70.
19
Pawlowski C, Wagner T, Puranik A, Murugadoss K, Loscalzo L, Venkatakrishnan A, et al. Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). Elife 2020:59209.
20
Klok F, Kruip M, Van Der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020:145–7.
21
Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 2021:45–57.
22
Lippi G, Favaloro E. D-dimer is associated with severity of coronavirus disease 2020: a pooled analysis. ThrombHaemost 2020:876–8.
23
Kunutsor S, Laukkanen J. Incidence of venous and arterial thromboembolic complications in CO-VID-19: A systematic review and meta-analysis. Thromb Res 2020:27–30.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
